SCHEMBL13279178

SCHEMBL13279178

CC(C)(C)OC(=O)N1CCN(c2ccc3cc(O)ccc3n2)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.58
PDE10A Q9Y233 3/20 0.49
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
ESR2 Q92731 1/20 0.47
GPR119 Q8TDV5 6/20 0.45
BACE1 P56817 1/20 0.45
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
SUV39H2 Q9H5I1 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
TLR9 Q9NR96 1/20 0.43
HTR3A P46098 1/20 0.42
HRH4 Q9H3N8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065311 0.87 HTR3A (0.60) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL29455913 0.87 MAP4K4 (0.57) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL15681568 0.86 MAP4K4 (0.56) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL15681567 0.84 MAP4K4 (0.54) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL4055019 0.84 PDE10A (0.64) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL16966823 0.83 SCN9A (0.48) ESR2GPR119BACE1ALDH1A1
SCHEMBL15447667 0.82 MAP4K4 (0.53) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL27952422 0.81 HCAR2 (0.47) ALDH1A1LMNAHTR3AHRH4
SCHEMBL25258149 0.81 MAP4K4 (0.58) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL15534608 0.80 MAPT (0.56) ESR2GPR119ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2697232-B1 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES OTSUKA PHARMA CO LTD (JP) 2016-05-18 EP disclosed
US-9051333-B2 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-06-09 US disclosed
EP-2697232-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-02-19 EP disclosed
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
WO-2012141338-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES BRD1, OXA1L, QDPR MAP4K4 1356/4885PDE10A 3984/4885CKS1B 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.